USA – FDA establishes advisory committee for genetic metabolic disease treatments

The US Food and Drug Administration (FDA) has announced the establishment of a new advisory committee to evaluate potential treatments for genetic metabolic diseases.

The Genetic Metabolic Diseases Advisory Committee will advise the FDA on products used for the diagnosis, prevention and treatment of genetic metabolic diseases under the Division of Rare Diseases and Medical Genetics, established in 2020.

Genetic metabolic diseases are conditions that disrupt an individual’s metabolism, which is the mechanism responsible for transferring food into energy and removing toxins from the body…